Apr 22,2019

Susmed: Demonstration of Clinical Data Managing System Using Blockchain Technology

Susmed is a Japanese leading digital therapeutics startup and is focusing on the research and development of smartphone applications as software medical devices for treatment of diseases such as insomnia. Company today announced that “Regulatory Sandbox System”, pilot projects led by Japanese government, on the “Demonstration of Clinical Data Monitoring System Using Blockchain Technology”, has been certified by the Ministry of Health, Labor, and Welfare and the Minister of Economy, Trade and Industry. In this pilot project, the system uses blockchain technology, which is expected to be more cost-effective than conventional methods in monitoring of clinical researches and ensuring data accuracy during monitoring.

PRODUCT

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
May 20,2019

Big Health’s digital therapeutic for sleep now available to over 12 million people worldwide

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced over 12 million people now have access to their flagship product, Sleepio. Thanks to a partnership with the UK’s National Health Service (NHS), 8 million Londoners and 2.3 million in the Thames Valley now have free access to Sleepio, an evidence-based digital therapeutic for poor sleep. Combined with another 2 million covered employees at Big Health employer customers in the United States, Big Health’s total covered population amounts to over 12 million individuals.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 18,2019

CVS Health kicks off digital health-friendly service for PBM clients with Big Health’s Sleepio

CVS Health unveiled Vendor Benefit Management, a new service that will help CVS Caremark pharmacy benefit management (PBM) clients roll out and manage third-party health products. As the service is applicable to both digital and non-digital health and wellness products, the company has decided to inaugurate its initiative by announcing Big Health — maker of the CBT-based sleep app Sleepio — as the first vendor participating in the service.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 25,2018

Big Health’s CBT app improves conditions of users with insomnia symptoms

A new dual-arm randomized trial published this morning in JAMA Psychiatry found that use of Big Health’s Sleepio app as a digital cognitive behavioral therapy (dCBT) led to significant improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life among those with symptoms to insomnia. Among a study group of 1,711 users, use of the Sleepio app appeared to drive improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 12,2018

Some Apps May Help Curb Insomnia, Others Just Put You To Sleep

Sleepio and a few other apps like SHUT-i and a free one developed by the Veterans Administration use the most sustainable and evidence-based solution for insomnia. It's a kind of therapy called Cognitive Behavioral Therapy for Insomnia — CBT-I.

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Twill and Zuellig Pharma Partner to Commercialize Prescription Digital Therapeutics in Asia

Today, Happify Health, the Intelligent Healing Company™, announced it has entered into an out-licensing and distribution deal with Zuellig Pharma for two of its digital therapeutics solutions. Zuellig Pharma, one of the largest healthcare services groups in Asia, will license Ensemble, Happify Health’s transdiagnostic prescription digital therapeutic for people with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) or both, and also license a Prescription Digital Therapeutics for the treatment of Chronic Insomnia. Zuellig Pharma will be deploying these solutions in 13 countries throughout the region.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Pear Therapeutics Announces Data from Two Studies Evaluating Prescription Digital Therapeutics (PDTs) for Chronic Insomnia Presented at World Sleep Congress 2022

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced data that further underscore the effectiveness of Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia. Interim data showed, by end of treatment, 78.7% and 73.3% of participants treated with Somryst achieved the American Academy of Sleep Medicine (AASM) clinically meaningful definition of sleep onset latency remission. Final results were presented in a symposia at World Sleep 2022, the international Congress of World Sleep Society, on March 15 in Rome, Italy.

CLINICAL STUDY

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 21,2022

Pear Therapeutics Announces Agreement with SoftBank Corp. to Develop a Digital Therapeutic for Sleep/Wake Disorders in Japan

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with SoftBank Corp. (“SoftBank”) to develop a Japanese-language digital therapeutic for the treatment of sleep/wake disorders for the Japanese market. In the United States, Pear is marketing Somryst®, the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia. In Japan, SoftBank is a leading communication and information technology service provider. This strategic initiative is a part of Pear’s strategy to commercialize digital therapeutics in international markets.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
May 04,2022

First-of-its-Kind Study Demonstrates Digital Therapeutic Significantly Improves Sleep and Mental Health for Stroke Patients

Big Health participated in a new, first-of-its-kind study in collaboration with the University of Oxford evaluating how a digital therapeutic for insomnia can benefit stroke patients with self-reported sleep issues. Preliminary outcomes found more than 48% of participants who utilized Sleepio – Big Health’s digital therapeutic for insomnia – experienced clinical improvement in sleep during post-stroke rehabilitation. In addition, the study found Sleepio users experienced less depression and anxiety 8-weeks post intervention. The study findings will be presented on May 4-6 at the European Stroke Organisation (ESO) conference being held in Lyon, France.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 14,2022

The Potential of Sleepio and CBT in the Poststroke Recovery Process

NeurologyLive spoke with Colin Espie, PhD, cofounder and chief scientist, Big Health, and professor of sleep medicine, University of Oxford, to find out more about the cognitive behavioral therapy (CBT) platform and the findings in the latest study.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to INSOMNIA